Immunoprecipitation
Cells attached to culture dishes were quickly washed once with a large volume (20-30 ml) of ice-cold PBS, snap-frozen in a liquid nitrogen bath and stored at -80 o C until further processing. Cells were lysed in 700 µl PK lysis buffer (50 mM Tris-HCl pH 7.5, 1 mM EDTA, 150 mM NaCl, 1% Igepal-630) supplemented freshly prior to use with protease inhibitors [10 µg/ml phenymethylsulfonyl fluoride, 4 µg/ml aprotinin, 4 µg/ml leupeptin, and 4 µg/ml pepstatin (pH 7.4)] and 1 mM dithiothreitol (DTT). Lysates were centrifuged (20,000xg, 10', at 4 o C), supernatants were transferred to fresh eppendorf tubes containing 20 µl of 50% Flag-agarose (Sigma-A2220) bead slurry in PK lysis buffer and incubated rotating at 4 o C for 1 hr. Under these conditions, lysates were immunodepleted of detectable Flag-tagged proteins. Immunoprecipitates were washed 4 times with PK lysis buffer (1ml=100 bead-volumes per wash) then eluted from beads with 3xFlag peptide (150 µg/ml final concentration, Sigma, F4799, dissolved in 50 mM Tris-HCl pH 7.4, 150 mM NaCl) for 30' rotating at 4 o C. Following a brief centrifugation of the beads, eluates were transferred to fresh eppendorf tubes, supplemented with SDS-PAGE loading buffer and analyzed by SDS-PAGE.
Xenograft experiments
H1299 parental and H1299 cells with constitutive expression of a mouse PKM1 cDNA (H1299-PKM1 cells) were propagated in RPMI supplemented with 10% fetal bovine serum, penicillin/streptomycin, 2 mM glutamine, and hygromycin for transgene selection. Cells were harvested, resuspended in sterile PBS, and 5x10 6 cells were injected subcutaneously into nu/nu mice. Tumor growth was monitored by caliper measurement, the mice were sacrificed and tumors harvested after the time indicated. Tumors were weighed, divided and either flash-frozen in liquid nitrogen or fixed in formalin for later analysis.
PKM2 activity assay
Pyruvate kinase activity was measured by monitoring pyruvate-dependent conversion of NADH to NAD + by lactate dehydrogenase (LDH) as described previously 32 . Briefly, for cell line experiments, the medium was replaced with fresh medium 1 hour prior to the start of treatment with DMSO or activator. Also, where indicated, 100 µM pervanadate was added 10 minutes prior to cell lysis. Cells were lysed on ice with NP-40 buffer containing 2mM DTT and protease inhibitors and clarified by centrifugation at 21,000 x g. 5 µl of the supernatant was used to assess pyruvate kinase activity 32 . Pyruvate kinase activity was subsequently normalized for total protein content. For the experiment in Supplementary Fig. 3f , the amino acid sequences of the peptides were: GGAVDDDYAQFANGG (M2tide) and GGAVDDDpYAQFANGG (P-M2tide) 17 .
Sucrose-gradient ultracentrifugation
Approximately 2.3ml of a 10-40% sucrose gradient was layered in ultracentrifuge tubes and left to equilibrate overnight. Recombinant PKM2 (purified as described below) was incubated with 500 nM TEPP-46, 1 µM DASA-58, or 100 µM FBP for 30 minutes on ice before layering on top of the gradient. For assessing the ability of FBP to stabilize PKM2 tetramers, 100 µM FBP was included in the sucrose gradient. Where indicated, recombinant PKM2 was transiently exposed to 100 µM FBP prior to addition of TEPP-46, but FBP was not present in the sucrose gradient. The gradients were then spun at 55,000 rpm for 10 hours using a Beckman TLS-55 rotor and fractions collected. The resulting fractions were analyzed by SDS-PAGE and Coomassie blue staining. Intensity of staining was quantified using IR fluorescence on a LiCOR Odyssey instrument.
Size exclusion chromatography
Recombinant protein or ~2 mg of cellular protein from hypotonically lysed cells was separated on a HiPrep 16/60 Sephacryl S-200 HR column (GE) in 50 mM sodium phosphate, 150 mM sodium chloride, pH 7.2. Fractions were analyzed by UV absorbance or SDS-PAGE and Western blot as indicated. For the experiment in Supplementary Fig. 3e the peptides used are the same as described under "PKM2 activity assay."
Cloning, expression, and purification of full length PKM2 for crystallization
The cDNA sequence of full-length human PKM2 was amplified by PCR and cloned into the expression plasmid pET28a-LIC, and the construct was verified by DNA sequencing. The resultant plasmid was transformed into Escherichia coli strain BL21(DE3) and the cells were grown in Terrific Broth at 37°C with 50 µg/ml kanamycin. When the OD 600 reached 1.0, the cells were induced by the addition of 0.5 mM isopropyl β-D-thiogalactoside (IPTG) for overnight at 18°C and the recombinant PKM2 was expressed as a His-tagged fusion protein containing 19 N-terminal amino acid residues (MGSSHHHHHHSSGLVPRGS). Cells were harvested by centrifugation, frozen in liquid nitrogen, and stored at -80°C. The thawed cell pellet was resuspended in binding buffer (10 mM HEPES, pH 7.5; 300 mM KCl; 5 mM imidazole, 5 mM MgCl 2 ; 5% glycerol; 2.5 mM TCEP) supplemented with protease inhibitor cocktail (Sigma) and 0.5% CHAPS, and then lysed by sonication. The lysate was clarified by centrifugation, and the supernatant was loaded onto DE52 column (Whatman) pre-equilibrated with binding buffer. The collected flow-through was loaded again onto Ni-NTA gravity flow column (Qiagen) equilibrated with binding buffer, and the bound His-tagged PKM2 protein was then eluted with elution buffer (10 mM HEPES, pH 7.5; 300 mM KCl; 5 mM imidazole; 5 mM MgCl 2 ; 5% glycerol; 2.5 mM TCEP). The fractions eluted from Ni-NTA column were pooled, concentrated, and loaded onto a HiLoad 26/60 Superdex 200 column (Amersham Biosciences) pre-equilibrated with 10 mM HEPES, pH 7.5; 100 mM KCl; 5 mM MgCl 2 ; 5% glycerol; 2.5 mM TCEP. The fractions containing PKM2 protein were collected, concentrated to 20 mg/mL using Amicon Ultra-15 centrifugal filter device (Millipore), and stored at -80°C until use. The final protein purity was confirmed by SDS-PAGE.
Protein crystallization, data collection and structure determination
For co-crystallization, the purified PKM2 was incubated overnight at room temperature in the presence of 5 mM activators (TEPP-46 or DASA-58) and then crystallization trays were set up using the sitting-drop vapor diffusion method with droplets of protein solution (0.5 µl) and reservoir solution (0.5 µl). The best diffracting crystals were obtained within 2 days from a reservoir solution containing 25% P3350, 0.2 M NH 4 OAc and 0.1 M Bis-Tris pH 6.5. Crystals were cryo-protected with 50% Paratone-N, 50% mineral oil for freezing them directly in liquid nitrogen for x-ray data collection. Data collection was carried out at the Advanced Photon Source beamline 23ID-B. For each complex crystal, 360 0.5° oscillation images were collected in a continuous sweep. 
Expression and purification of recombinant PKM2 for other studies
Recombinant His-tagged PKM2 was prepared for ultracentrifugation essentially as above, except that transformed E. coli BL21(DE3) cells were grown in LB broth containing 2mM MgCl 2 at 37°C with 50 µg/ml kanamycin until OD 600 reached 0.7. The culture was transferred to room temperature, induced with 0.5 mM IPTG for 6 hours and harvested as described. The cell pellet was resuspended in binding buffer (50 mM Tris, pH 8.5; 10 mM MgCl 2 ; 300 mM NaCl; 10% glycerol; 5mM imidazole), and sonicated. The lysate was clarified by centrifugation, supplemented with 0.1% (v/v) 2-mercaptoethanol, and bound to pre-equilibrated Ni-NTA agarose beads (Qiagen) by gentle shaking on ice for 3 hours. The beads were batch-washed four times in wash buffer (50 mM Tris, pH 8.5; 10 mM MgCl 2 ; 300 mM NaCl; 10% glycerol; 30mM imidazole), then packed into a gravity flow column. Bound protein was eluted in elution buffer (50 mM Tris, pH 8.5; 10 mM MgCl 2 ; 250 mM NaCl; 10% glycerol; 250mM imidazole) and fractions were collected and analyzed by Bradford assay or SDS-PAGE with Coomassie blue staining prior to pooling. Pooled fractions were dialyzed overnight in dialysis buffer (50 mM Tris, pH 7.5; 10 mM MgCl 2 ; 25 mM NaCl; 20% glycerol; 0.15% 2-mercaptoethanol), then for an additional 8 hours in fresh dialysis buffer.
Cell doubling time
20,000 cells were seeded in 12-well plates at day -1 in media containing 5.6 mM D-glucose and incubated at the indicated O 2 concentrations. In all cases media contained 10% dialyzed FCS and 20 mM HEPES pH 8.0. At day 0 the media were replaced with fresh media that had been equilibrated since the time of cell seeding at 37 o C under the corresponding oxygen concentrations. At days 0, 2, 4 and 6 cells were fixed with 10% formalin and at the end of the experiment stained with 0.1% w/v crystal violet in 20% methanol, shaking for 15' at room temperature, and washed with water twice for 10' each; the plates were then dried on air. Cell-bound crystal violet was solubilized in 1 ml 10% v/v acetic acid and, because the amount of dye bound to cells is proportional to the number of cells, accumulation of cell mass was assessed by measurement of crystal violet absorbance at 595 nm in a spectrophotometer. Doubling times were calculated using exponential regression (http://www.doubling-time.com/compute.php).
Protein identification by LC-MS/MS
For all mass spectrometry (MS) experiments, pyruvate kinase immunoprecipitates were separated using SDS-PAGE, the gel was stained with Coomassie blue, destained and the pyruvate kinase band was excised. Samples were washed with 50% acetonitrile, subjected to reduction with 10mM dithiothreitol (DTT) for 30 minutes, alkylation with 55mM iodoacetamide with 45 minutes, and in-gel digestion with TPCK modified trypsin (Promega) or chymotrypsin (Princeton Scientific) overnight at pH 8.3, followed by reversed-phase microcapillary/tandem mass spectrometry (LC/MS/MS). LC/MS/MS was performed using an EASY-nLC splitless nanoflow HPLC (Thermo Fisher Scientific) with a self-packed 75 µm i.d. x 15 cm C18 Picofrit column (New Objective) coupled to a LTQ-Orbitrap XL mass spectrometer (Thermo Scientific) in data-dependent positive ion mode at 300 nL/min with one full MS-FT scan followed by six MS/MS-IT scans via collision induced dissociation (CID). MS/MS spectra were searched against the concatenated target and decoy (reversed) Swiss-Prot protein database using Sequest (Proteomics Browser Software (PBS), Thermo Fisher Scientific) with differential modifications for Met oxidation (+15.99), deamidation of Asn and Gln (+0.984) and fixed Cys alkylation (+57.02). Peptide sequences were identified if they initially passed the following Sequest scoring thresholds against the target database: 1+ ions, Xcorr ≥ 2.0 Sf ≥ 0.4, P ≥ 5; 2+ ions, Xcorr ≥ 2.0, Sf ≥ 0.4, P ≥ 5; 3+ ions, Xcorr ≥ 2.60, Sf ≥ 0.4, P ≥ 5 against the target protein database. Passing MS/MS spectra were manually inspected to be sure that all b-and y-fragment ions aligned with the assigned sequence. False discovery rates (FDR) of peptide hits were estimated below 1.5% based on reversed database hits.
Metabolism measurements
For measurement of glucose-dependent lipid synthesis 31 , 10 5 cells per well were seeded in 12-well plates at t=-24 hours. At t=-1 hour the medium was changed to fresh growth medium containing activator as indicated in the figure legend. At t=0 the medium was replaced with fresh growth medium containing 4 µCi/ml [6-14 C]glucose (final concentration=72 µM) and activator as indicated. Cells were then incubated for 2 hours at 37 o C, 5% CO 2 . The labeling medium was then removed, cells were washed once with PBS at room temperature and lipids were extracted twice with 500 µl hexane:isopropanol (3:2 v/v), extracts were pooled and dried under nitrogen. Dried lipids were resuspended in 100 µl chloroform and radioactivity was measured in a scintillation counter. Lactate levels were measured using YSI 7100 Select Biochemistry Analyzer (YSI Incorporated). Oxygen consumption rates were measured using a polarographic oxygen electrode 40 .
MTS cell viability assay 2,000 cells were seeded in 96-well plates 24 h prior to treatment start. CellTiter96 ® AQ ueous (Promega-G5421) was used according to the manufacturer's protocol to assess cell viability following oxidant and PKM2 activator combination treatments. MTS: (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium).
GC/MS and analysis of lipid synthesis
For determination of [U-13 C 6 ]glucose enrichment in lipogenic AcCoA, A549 cells were cultured for 3 days in the presence of tracer and either DMSO or 100 µM DASA-58. For extraction, cells were rinsed with 1 ml ice cold PBS and quenched with 0.4 ml ice cold methanol. An equal volume of water was added, and cells were collected in tubes by scraping with a pipette. One volume of ice-cold chloroform was added to each tube, and the extracts were vortexed for 15 minutes. Samples were centrifuged at 14,000 g for 5 minutes at room temperature, and the nonpolar fraction was collected in a fresh tube and evaporated under airflow. Fatty acid methyl esters were generated from lipid biomass by dissolving dried chloroform fractions in 50 µl of Methyl-8 reagent (Pierce) and incubating at 60°C for 1 hour. GC/MS analysis was performed using an Agilent 6890 GC equipped with a 30m DB-35MS capillary column connected to an Agilent 5975B MS operating under electron impact (EI) ionization at 70 eV. One µl of sample was injected in splitless mode at 270°C, using helium as the carrier gas at a flow rate of 1 ml min -1 . The GC oven temperature was held at 100°C for 5 minutes after injection, increased to 200°C at 15° min -1 , then to 250°C at 5° min -1 , and finally to 300°C at 15° min -1 . The MS source and quadrupole were held at 230°C and 150°C, respectively, and the detector was run in scanning mode, recording ion abundance in the range of 100 -350 m/z. Mass isotopomer distributions (MIDs) were determined by integrating palmitate ion fragments in the m/z range of 270 to 286. Computational estimation of AcCoA enrichment and fractional new palmitate synthesis was accomplished as previously described 45, 46 . Associated 95% confidence intervals were calculated by performing parameter continuation as described 47, 48 .
Metabolite analysis by targeted liquid-chromatography tandem mass spectrometry (LC-MS/MS)
For tissue culture experiments, 48 hours prior to each experiment, 2.5x10 5 cells were seeded in 6 cm dishes in media without sodium pyruvate, containing 10% dialyzed FCS, 2 mM glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin. Media were changed at t=-24 h and t=-2 h. At t=0h cells were harvested at the indicated time points as follows: media were aspirated and metabolites were extracted with 1.5 ml of 4:1 v/v MeOH/H 2 O equilibrated at -80 o C. The extract and cells were scraped and collected into 15 ml conical tubes and centrifuged for 5 minutes at 690xg and solvent in the resulting supernatant was evaporated using a speed-vac. For xenograft experiments, mice bearing H1299 xenograft tumors were treated orally with TEPP-46 at 50mg/kg 16 and 4 hours before tumor harvest. Metabolites from snap-frozen xenograft tumor tissue were extracted with 4:1 v/v MeOH/H 2 O equilibrated at -80 o C, and supernatants were dried under nitrogen gas. Samples were re-suspended in 20µL HPLC-grade water for mass spectrometry. 8 µL were injected and analyzed using a 5500 QTRAP triple quadrupole mass spectrometer (AB/SCIEX) coupled to a Prominence UFLC system (Shimadzu) via selected reaction monitoring (SRM) of 253 in total endogenous water-soluble metabolites 42 . Some metabolites were targeted in both positive and negative ion mode for a total of 287 SRM transitions. ESI voltage was +4900V in positive ion mode and -4500V in negative ion mode via positive/negative polarity switching. The dwell time was 3 ms per SRM transition and the total cycle time was 1.57 seconds. Approximately 10-14 data points were acquired per detected metabolite. Samples were delivered to the MS via normal phase chromatography using a 4.6 mm i.d. x 10 cm Amide XBridge HILIC column (Waters) at 350 µL/minutes Gradients were run starting from 85% buffer B (HPLC grade acetonitrile) to 42% B from 0-5 minutes; 42% B to 0% B from 5-16 minutes; 0% B was held from 16-24 minutes; 0% B to 85% B from 24-25 minutes; 85% B was held for 7 minutes to re-equilibrate the column. MS data were acquired during the first 15 minutes of the LC gradient. Buffer A was comprised of 20 mM ammonium hydroxide/20 mM ammonium acetate (pH=9.0) in 95:5 water:acetonitrile. Peak areas from the total ion current (TIC) for each metabolite SRM transition were integrated using MultiQuant v2.0 software (AB/SCIEX). Integrated TIC areas corresponding to metabolite concentrations were imported into Metaboanalyst 43 software, subjected to quantile normalization and statistical significance of changes in metabolite concentrations between different genotypes and treatments were determined by ANOVA.
ADME and PK/PD methods
Pharmacokinetic studies were performed in male BALB/c mice fasted from 2 hr pre-dose to 2 hr post-dose. TEPP-46 was formulated as 40% beta-hydroxy cyclodextrin in water (for IV, IP) or 0.5% carboxy methyl cellulose (400-1000 cps) with 0.1 % v/v Tween 80 (for PO). For intravenous administration, the solution of TEPP-46 was administered as bolus injection at 1 mg/kg dose via tail vein with 5 mL/kg volume at a slow and steady rate. For intraperitoneal route, TEPP-46 was administered at 10 mg/kg and 50 mg/kg doses through the peritoneum cavity with a dosing volume of 10 mL/kg. For oral dosing, the test compound was administered as uniform suspension at 10 mg/kg dose via stomach intubation using a 16-gauge oral feeding needle with a dosing volume of 10 mL/kg. Blood samples (0.06 mL) were collected from retro-orbital sinus of a set of three mice each at t=0, 0.08 (IV and IP), 0.25, 0.5, 1, 2, 4, 6 (only for PO), 8 and 24 hr in pre-labeled microtubes containing EDTA as anticoagulant. The plasma samples were stored at -70ºC until bioanalysis by LC-MS/MS with lowest level of quantitation (LLOQ) = 0.636 ng/mL. Pharmacokinetics parameters (C max , T max , T ½ , AUC) were calculated using non-compartmental model with WinNonlin Ver 5.2 as statistics software (Pharsight Corporation, California, USA).
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Yang Lysates of mouse muscle or liver tissue (which express exclusively PKM1 and PKL, respectively) and 293T cells (which express exclusively PKM2) were utilized as controls for isoform-specificity of the antibodies. Lysates were analyzed by SDS-PAGE and Western blot with antibodies specific to the indicated isoforms or an antibody (PKM) that recognizes both PKM1 and PKM2. (b) Lysates of H1299 cells expressing Flag-PKM1 or Flag-PKM2 generated as in (a) were subjected to immunoprecipitation with Flag-antibodies to immunoprecipitate Flag-PKM1 or Flag-PKM2. Immunoprecipitated proteins were visualized by silver staining. (c) Peptide maps derived from mass spectrometry analysis of the corresponding bands in (b). Yellow highlights indicate protein sequence coverage; green lines indicate detected peptides; red lines indicate the protein sequence encoded by the PKM1-specific or PKM2-specific exons. This spans a region of 55 aminoacids (residues 381-435) of which 21 are distinct between the two isoforms allowing unequivocal identification. It remains unclear if the increased pyruvate kinase activity in cells following PKM1 expression results from PKM1 alone or the ability of PKM1 to increase the activity of PKM1/PKM2 heterocomplexes. However, the latter possibility seems likely as Flag-PKM1 coprecipitates equivalent amounts of endogenous PKM2 (Supplementary Fig. 3e ). Immunoprecipitates were analyzed by SDS-PAGE and the amount of endogenous PKM2 coprecipitating with Flag-PKM2 was assessed by Western blot with a PKM2 antibody. (g) H1299 cells were treated with 100 µM pervanadate for 10 minutes in the presence or absence of TEPP-46, lysed hypotonically, and were analyzed by size exclusion chromatography as in Fig. 3b . Chromatographic fractions were then subjected to Western blotting with a pyruvate kinase antibody to assess the stoichiometry of PKM2 subunit association under these conditions. (h) Purified recombinant PKM2 expressed in bacteria was treated with a phosphotyrosine-containing peptide with amino acid sequence corresponding to the optimal PKM2 binding sequence (pM2tide) or a peptide with the same sequence but lacking the phosphate on the tyrosine (M2tide). Following incubation with the peptides, PKM2 subunit composition in each sample was analyzed by sizeexclusion chromatography. (i) Purified recombinant PKM2 was treated with M2tide or pM2tide as in (g) in the presence of increasing concentrations of TEPP-46 and assayed for pyruvate kinase activity. Supplementary Fig. 4 | (a human medullary thyroid carcinoma, H1299: human non-small cell lung carcinoma, SN12C: human renal cell carcinoma, SKMel28: human melanoma, A549: human non-small cell lung carcinoma). Cells were treated with the indicated doses of DASA-58 for 72 hours at which point viability was assayed using an MTS assay. 
